BrightGene Other Assets vs Net Working Capital Analysis
688166 Stock | 30.14 1.06 3.40% |
BrightGene Bio financial indicator trend analysis is way more than just evaluating BrightGene Bio Medical prevailing accounting drivers to predict future trends. We encourage investors to analyze account correlations over time for multiple indicators to determine whether BrightGene Bio Medical is a good investment. Please check the relationship between BrightGene Bio Other Assets and its Net Working Capital accounts. Check out Trending Equities to better understand how to build diversified portfolios. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in nation.
Other Assets vs Net Working Capital
Other Assets vs Net Working Capital Correlation Analysis
The overlapping area represents the amount of trend that can be explained by analyzing historical patterns of BrightGene Bio Medical Other Assets account and Net Working Capital. At this time, the significance of the direction appears to have very strong relationship.
The correlation between BrightGene Bio's Other Assets and Net Working Capital is 0.81. Overlapping area represents the amount of variation of Other Assets that can explain the historical movement of Net Working Capital in the same time period over historical financial statements of BrightGene Bio Medical, assuming nothing else is changed. The correlation between historical values of BrightGene Bio's Other Assets and Net Working Capital is a relative statistical measure of the degree to which these accounts tend to move together. The correlation coefficient measures the extent to which Other Assets of BrightGene Bio Medical are associated (or correlated) with its Net Working Capital. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when Net Working Capital has no effect on the direction of Other Assets i.e., BrightGene Bio's Other Assets and Net Working Capital go up and down completely randomly.
Correlation Coefficient | 0.81 |
Relationship Direction | Positive |
Relationship Strength | Strong |
Other Assets
Net Working Capital
Most indicators from BrightGene Bio's fundamental ratios are interrelated and interconnected. However, analyzing fundamental ratios indicators one by one will only give a small insight into BrightGene Bio Medical current financial condition. On the other hand, looking into the entire matrix of fundamental ratios indicators, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out Trending Equities to better understand how to build diversified portfolios. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in nation. As of February 5, 2025, Tax Provision is expected to decline to about 14.9 M. In addition to that, Selling General Administrative is expected to decline to about 73.5 M
2022 | 2023 | 2024 | 2025 (projected) | Gross Profit | 641.0M | 658.1M | 756.8M | 438.0M | Total Revenue | 1.0B | 1.2B | 1.4B | 751.2M |
BrightGene Bio fundamental ratios Correlations
Click cells to compare fundamentals
BrightGene Bio Account Relationship Matchups
High Positive Relationship
High Negative Relationship
BrightGene Bio fundamental ratios Accounts
2020 | 2021 | 2022 | 2023 | 2024 | 2025 (projected) | ||
Total Assets | 1.8B | 3.0B | 4.7B | 5.0B | 5.8B | 6.1B | |
Other Current Liab | 32.0M | 25.9M | 50.7M | 20.1M | 18.1M | 26.6M | |
Total Current Liabilities | 291.7M | 583.1M | 811.5M | 922.2M | 1.1B | 1.1B | |
Total Stockholder Equity | 1.4B | 1.7B | 2.2B | 2.4B | 2.7B | 1.4B | |
Net Tangible Assets | 1.3B | 1.4B | 1.6B | 2.1B | 2.4B | 1.2B | |
Retained Earnings | 345.5M | 555.1M | 743.4M | 830.4M | 955.0M | 1.0B | |
Accounts Payable | 79.6M | 211.9M | 252.2M | 228.2M | 262.4M | 275.5M | |
Cash | 339.5M | 336.8M | 1.2B | 998.0M | 1.1B | 1.2B | |
Non Current Assets Total | 881.4M | 2.0B | 2.7B | 3.2B | 3.7B | 3.9B | |
Non Currrent Assets Other | 628.5M | 115.9M | 300.9M | 233.3M | 268.3M | 184.6M | |
Other Assets | 56.8M | 223.3M | 161.5M | 351.7M | 404.5M | 424.7M | |
Net Receivables | 177.3M | 373.3M | 302.8M | 283.0M | 325.4M | 224.4M | |
Non Current Liabilities Total | 103.5M | 644.9M | 1.6B | 1.7B | 1.9B | 2.0B | |
Inventory | 203.2M | 200.1M | 280.4M | 344.6M | 396.3M | 416.1M | |
Other Current Assets | 39.6M | 73.3M | 95.4M | 65.2M | 75.0M | 49.4M | |
Total Liab | 395.2M | 1.2B | 2.4B | 2.6B | 3.0B | 3.2B | |
Deferred Long Term Liab | 22.9M | 33.0M | 25.8M | 26.9M | 30.9M | 26.2M | |
Total Current Assets | 946.4M | 993.0M | 1.9B | 1.8B | 2.1B | 1.1B | |
Intangible Assets | 48.8M | 80.8M | 81.6M | 93.7M | 107.7M | 113.1M | |
Property Plant Equipment | 244.7M | 452.5M | 1.4B | 2.1B | 2.4B | 2.5B | |
Net Invested Capital | 1.7B | 2.6B | 4.2B | 4.1B | 4.8B | 5.0B | |
Net Working Capital | 654.7M | 409.9M | 1.1B | 917.5M | 1.1B | 745.5M | |
Other Stockholder Equity | (7.2M) | (24.8M) | (25.8M) | 17.8M | 20.4M | 21.5M | |
Property Plant And Equipment Net | 452.5M | 1.4B | 2.1B | 2.5B | 2.9B | 1.5B | |
Property Plant And Equipment Gross | 577.3M | 1.5B | 2.1B | 2.7B | 3.1B | 1.6B |
Currently Active Assets on Macroaxis
EBR | Centrais Electricas Brasileiras | |
HE | Hawaiian Electric Industries | |
VFC | VF Corporation | |
BVHMF | Vistry Group PLC | |
S | SentinelOne |
Other Information on Investing in BrightGene Stock
Balance Sheet is a snapshot of the financial position of BrightGene Bio Medical at a specified time, usually calculated after every quarter, six months, or one year. BrightGene Bio Balance Sheet has two main parts: assets and liabilities. Liabilities are the debts or obligations of BrightGene Bio and are divided into current liabilities and long term liabilities. An asset, on the other hand, is anything of value that can be converted into cash and which BrightGene currently owns. An asset can also be divided into two categories, current and non-current.